Daily feed · SEC Form 4 filings
Insider buying in low-priced stocks — Jul 26, 2017
Open-market purchases where the filing’s own weighted average price is under $5. Price comes from the Form 4 itself, not a market quote.
| Trade | Reported (ET) | Company | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 25, 2017 PForm 4 → | Jul 25, 6:06 pm EDT | Regulus Therapeutics Inc.RGLS | Stelios PapadopoulosDirector | 1,000,000 | $0.91 | $910,000 | 1,770,677 | +130% | plan? |
| Jul 25, 2017 PForm 4 → | Jul 25, 6:09 pm EDT | Regulus Therapeutics Inc.RGLS | William H RastetterDirector | 274,725 | $0.91 | $250,000 | 624,625 | +78.5% | plan? |
| Jul 25, 2017 PForm 4 → | Jul 25, 6:09 pm EDT | Regulus Therapeutics Inc.RGLS | Timothy Michael WrightChief R & D Officer | 274,725 | $0.91 | $250,000 | 274,725 | — | plan? |
| Jul 25, 2017 PForm 4 → | Jul 25, 6:08 pm EDT | Regulus Therapeutics Inc.RGLS | Joseph P HaganPresident and CEO, Director | 219,780 | $0.91 | $200,000 | 241,297 | +1,021% | plan? |
| Jul 25, 2017 PForm 4 → | Jul 25, 6:07 pm EDT | Regulus Therapeutics Inc.RGLS | Daniel R. ChevallardChief Financial Officer | 54,945 | $0.91 | $50,000 | 59,415 | +1,229% | plan? |
| Jul 21, 2017 PForm 4 → | Jul 25, 5:29 pm EDT | MYnd Analytics, Inc.MYND | John PappajohnDirector, 10% Owner | 10,000 | $4.25 | $42,493 | 526,290 | +1.94% | plan? |
| Jul 26, 2017 PForm 4 → | Jul 26, 3:42 pm EDT | LUBYS INCLUB | K Scott GraySVP & Chief Financial Officer | 1,000 | $2.85 | $2,850 | 47,564 | +2.15% | plan? |
| Jul 24, 2017 PForm 4 → | Jul 25, 5:14 pm EDT | CareDx, Inc.CDNA | Neil Gagnon10% Owner | 1,486 | $1.23 | $1,828 | 955,758 | +0.16% | plan? |
| Jul 24, 2017 PForm 4 → | Jul 25, 4:19 pm EDT | AMARILLO BIOSCIENCES INCAMAR | Stephen T ChenPresident, CEO & Chairman, Director, 10% Owner | 2,000 | $0.2825 | $565 | 117,477 | +1.73% | plan? |
A trading day runs to 4:00 pm ET; filings accepted later appear on the next trading day. Rows aggregate a filing’s matching transaction lines — see the methodology for the exact roll-up rules.